Please login to the form below

Not currently logged in
Email:
Password:

monoclonal antibodies

This page shows the latest monoclonal antibodies news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Summit's $12m lifeline, Biohaven's speech anxiety pill, Crescendo's Humabody progress

Daily Brief: Summit's $12m lifeline, Biohaven's speech anxiety pill, Crescendo's Humabody progress

The company is one of a number of biotechs looking to develop the next generation of biologics against cancer, aiming to reach targets on tumours currently inaccessible to conventional monoclonal antibodies. ... Compared to full antibodies, Humabodies

Latest news

More from news
Approximately 2 fully matching, plus 83 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Three CGRP monoclonal antibodies will launch in the US for migraine in 2018 - with a fourth anticipated in 2019.

  • The tipping point The tipping point

    For example, since 2015, when the first monoclonal antibody biosimilar, infliximab, was launched in Europe we have seen a notable increase in the overall use of infliximab. ... For example, providing therapeutic drug monitoring (TDM) to minimise loss of

  • What makes the difference in the biosimilar battle? What makes the difference in the biosimilar battle?

    Taking the example of multiple blockbuster monoclonal antibodies close to their patent expiry dates, we can see that numerous big pharma companies like Merck, Amgen and Pfizer and even smaller to

  • Deal Watch December 2016 Deal Watch December 2016

    511. BioInvent (Sweden). Pfizer (US). Research collaboration. Development of immuno-regulatory antibodies targeting tumour-associated myeloid cells. ... The other two companies, the Swedish company, BioInvent, and the British company, Abzena, have

  • Deal Watch April 2016 Deal Watch April 2016

    1, 200. ZymeWorks (US). GSK (UK). License and option. Preclinical bi-specific antibodies based on Azymetric platform for treatment of solid tumours. ... 125 . Enumeral (US). Pieris (DE). License &option to further programme. Discovery state 388D4

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

  • F-star appoints GSK's Neil Brewis F-star appoints GSK's Neil Brewis

    Brewis joins from GlaxoSmithKline where he served as vice president and head head of biopharmaceutical research, leading a global team of 300 scientists who advanced numerous monoclonal antibodies, antibody fragments, and

  • V Bryan Lawlis joins board of KaloBios V Bryan Lawlis joins board of KaloBios

    patient-targeted, monoclonal antibodies towards commercialisation,” said David Pritchard, president and CEO of KaloBios. ... This includes three antibodies in development: one for inflammatory disease, one for lung infection and one for cancer.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics